Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Hepatology (Baltimore, Md.) ; h5-index 0.0

Despite continued efforts, effective therapy for Primary Sclerosing Cholangitis (PSC) has not yet emerged. This is due to the challenges posed by a rare, heterogeneous disease that includes biliary fibro-inflammation alongside inflammatory bowel disease (IBD). Additional challenges include sub-optimal risk assessment, particularly at the individual level.

Shung Dennis L, Assis David N